SCHEMBL24791654

SCHEMBL24791654

c1cnc(-c2ccc(CNc3cc(N[C@H]4CCNC4)nc4c(C5CC5)cnn34)cc2)nc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDK7 P50613 7/20 0.44
▸ CDK2 P24941 6/20 0.44
▸ CDK9 P50750 5/20 0.44
▸ CDK1 P06493 4/20 0.44
▸ CCNE1 P24864 4/20 0.44
▸ CCNH P51946 4/20 0.44
▸ MNAT1 P51948 4/20 0.44
▸ CDK4 P11802 2/20 0.44
▸ CDK6 Q00534 2/20 0.44
▸ CDK5 Q00535 2/20 0.44
▸ CDK8 P49336 1/20 0.44
▸ CHEK1 O14757 2/20 0.43
▸ CCNA2 P20248 1/20 0.43
▸ CCNA1 P78396 1/20 0.43
▸ GSK3B P49841 3/20 0.42
▸ MAPKAPK2 P49137 1/20 0.41
▸ PRKCI P41743 1/20 0.40
▸ CCNT1 O60563 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24791653 0.95 CDK2 (0.47) CDK7CDK2CDK9CDK1CCNE1
SCHEMBL24791659 0.91 CDK2 (0.45) CDK7CDK2CDK9CDK1CCNE1
SCHEMBL24791683 0.91 CDK2 (0.45) CDK7CDK2CDK9CDK1CCNE1
SCHEMBL24791684 0.91 CDK2 (0.45) CDK7CDK2CDK9CDK1CCNE1
SCHEMBL24792726 0.88 CDK2 (0.42) CDK7CDK2CDK9CDK1CCNE1
SCHEMBL24792994 0.86 CDK7 (0.60) CDK7CDK2CDK9CDK1CCNE1
SCHEMBL24791508 0.86 CDK2 (0.49) CDK7CDK2CDK9CDK1CCNE1
SCHEMBL24791510 0.86 CDK2 (0.49) CDK7CDK2CDK9CDK1CCNE1
SCHEMBL24792971 0.85 CDK2 (0.47) CDK7CDK2CDK9CDK1CCNE1
SCHEMBL24791462 0.85 CDK7 (0.63) CDK7CDK2CDK9CDK1CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383900-A1 SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2024-11-21 — — US disclosed
CN-117940427-A Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof 卡里克治疗有限公司 2024-04-26 — — CN disclosed
EP-4355426-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2024-04-24 — — EP disclosed
WO-2022263604-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2022-12-22 — — WO disclosed
WO-2022263604-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2022-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383900-A1 SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE CDK3, CDK1, CDK2 CDK7 11/4885CDK2 3/4885CDK9 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback